Timber Pharma appoints CEO John Koconis to additional role of Board Chairman alongside Ed Sitar as Lead Independent Director

– USA, NJ –  Timber Pharmaceuticals, Inc. (NYSE: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that CEO John Koconis has been appointed to the additional role of Chairman of the Board of Directors.

The Company also announced that Ed Sitar has been appointed as Lead Independent Director of the Board and Dr. David Cohen will serve as Chair of the Company’s new Science and Technology Committee.

“This is a truly exciting time for Timber as we complete our initial year of operations as a public company and advance to late stages of clinical research, and I look forward to serving as Chairman of the Board in partnership with Mr. Sitar and our other experienced directors along with the excellent team we have in place,” said John Koconis, Chairman and CEO.

He added:We are also pleased to launch a new Science and Technology Committee that will be led by Dr. Cohen, a renowned expert in dermatology, which will guide our development programs targeting rare dermatologic conditions including congenital ichthyosis, facial angiofibromas, and sclerotic dermatologic diseases.”

About John Koconis

Mr. Koconis has served as CEO of Timber since 2019. As both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience, he has led successful teams in global markets launching products in a broad, specialty, and orphan dermatology. Mr. Koconis previously held leadership positions with LEO Pharma, Sanofi/Genzyme, and Castle Creek Pharmaceuticals.

About Edward Sitar

Mr. Sitar has served as a director on our Board since May 2020. Mr. Sitar has had extensive financial leadership experience. Since July 2019, Mr. Sitar has served as the Chief Financial Officer of 9 Meters Biopharma, Inc., formerly known as Innovate Biopharmaceuticals Inc., a clinical-stage biotechnology company. Mr. Sitar has extensive experience with public companies like Timber and the challenges growing companies face.

About Dr. David Cohen

Dr. David Cohen has also served on the Timber Board of Directors since 2020. He is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and Environmental Dermatology. In addition to his scientific credentials Dr. Cohen has also served on numerous public and private company boards.

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company’s investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and scleroderma.

For more information: https://www.timberpharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team